Dr. Reddy’s introduces ‘Dose Counter Inhalers’ for the first time in India
April15, 2010, Hyderabad: Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) has introduced an innovation in the Metered Dose Inhaler space with launch of ‘Dose Counter Inhalers’ (DCI) for the first time in India. This is the first Metered Dose Inhaler in India that gives patients an advance indication of when the Inhaler is going to be empty. The device also includes a retractable mouth piece and a child lock facility and comes with a "Universal Adapter" that can be fitted with available spacers.
Dose Counter Inhalers is a new drug delivery device with a single device having 120 metered doses.
Notes to the editor:
- Inhaler market is currently valued at Rs 629 crore growing at a CAGR of over 18% (Source: ORG
- Dr. Reddy’s had entered the respiratory inhaler segment in India with the launch of ‘Combihale™’ - a combination of a steroid and a long acting bronchodilator in September 2008. It is used in the treatment of asthma and is available in three combinations, Combihale™ FF (Formoterol + Fluticasone), Combihale™ FB (Formoterol + Budesonide) and Combihale™ FT (Formoterol + Tiotropium)
DPI Mode of action:
There is a window in the inhaler that changes colour from Green to Red. Green indicates the inhaler is full. Red Indicates the Inhaler is empty. Half Green and Half Red in the window indicate it’s time to change the inhaler.
This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.
About Dr. Reddy’s
Established in 1984, Dr. Reddy’s Laboratories (NYSE: RDY) is an emerging global pharmaceutical company. We
fulfill our purpose of providing affordable and innovative medicines through three core businesses:
Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products. Our products are marketed globally, with a focus on India, US, UK, Germany and Russia& CIS.
For more information please contact:
S Rajan at firstname.lastname@example.org / +91-40-66511725
Investors and Financial Analysts:
Kedar Upadhye at email@example.com / +91-40-66834297
Raghavender R at firstname.lastname@example.org / +91-40-66511529
Milan Kalawadia (USA) at email@example.com / +1 908-203-4931